Edition:
India

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
15 Dec 2017
Change (% chg)

$-0.02 (-2.41%)
Prev Close
$0.83
Open
$0.84
Day's High
$0.88
Day's Low
$0.80
Volume
64,741
Avg. Vol
180,186
52-wk High
$5.25
52-wk Low
$0.78

Select another date:

Fri, Nov 17 2017

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

BRIEF-Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM

* Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm

BRIEF-Delmar Pharmaceuticals appoints Saiid Zarrabian to board

* Delmar Pharmaceuticals appoints Saiid Zarrabian to the board of directors and names Erich Mohr as chairman

BRIEF-DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

* DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

Select another date: